Quarterly ResultAug 6, 2026, 08:13 AM
Aligos Therapeutics Reports $24.5M Net Loss; Raises Going Concern Doubt
AI Summary
Aligos Therapeutics reported a net loss of $24.5 million for the six months ended June 30, 2026, a significant decline from a net income of $27.2 million in the same period last year. The company disclosed substantial doubt about its ability to continue as a going concern, with current cash expected to fund operations only into the fourth quarter of 2026. Despite generating $27.8 million in licensing revenue, increased research and development expenses contributed to the overall loss and a higher cash burn from operations.
Key Highlights
- Company raised substantial doubt about its ability to continue as a going concern.
- Net loss of $24.5 million for six months ended June 30, 2026, compared to $27.2 million net income in prior year.
- Basic net loss per share was $2.36 for six months ended June 30, 2026, versus $2.90 income per share in prior year.
- Cash and cash equivalents were $30.4 million as of June 30, 2026.
- Net cash used in operating activities increased to $48.1 million for six months ended June 30, 2026.
- Revenue from licensing agreements was $27.8 million for six months ended June 30, 2026.
- Research and development expenses rose to $47.4 million for six months ended June 30, 2026.
Price Impact
More from ALGS